From bench to bedside: Lessons learned in translating preclinical studies in cancer drug development

Christopher H. Lieu, Aik Choon Tan, Stephen Leong, Jennifer R. Diamond, S Gail Eckhardt

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The development of targeted agents in oncology has rapidly expanded over the past 2 decades and has led to clinically significant improvements in the treatment of numerous cancers. Unfortunately, not all success at the bench in preclinical experiments has translated to success at the bedside. As preclinical studies shift toward defining proof of mechanism, patient selection, and rational drug combinations, it is critical to understand the lessons learned from prior translational studies to gain an understanding of prior drug development successes and failures. By learning from prior drug development, future translational studies will provide more clinically relevant data, and the underlying hope is that the clinical success rate will improve and the treatment of patients with ineffective targeted therapy will be limited.

Original languageEnglish (US)
Pages (from-to)1441-1456
Number of pages16
JournalJournal of the National Cancer Institute
Volume105
Issue number19
DOIs
StatePublished - Oct 2 2013

Fingerprint

Pharmaceutical Preparations
Neoplasms
Drug Combinations
Patient Selection
Therapeutics
Learning

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

From bench to bedside : Lessons learned in translating preclinical studies in cancer drug development. / Lieu, Christopher H.; Tan, Aik Choon; Leong, Stephen; Diamond, Jennifer R.; Eckhardt, S Gail.

In: Journal of the National Cancer Institute, Vol. 105, No. 19, 02.10.2013, p. 1441-1456.

Research output: Contribution to journalReview article

Lieu, Christopher H. ; Tan, Aik Choon ; Leong, Stephen ; Diamond, Jennifer R. ; Eckhardt, S Gail. / From bench to bedside : Lessons learned in translating preclinical studies in cancer drug development. In: Journal of the National Cancer Institute. 2013 ; Vol. 105, No. 19. pp. 1441-1456.
@article{b96628fe545749c8bf78cd752e58d283,
title = "From bench to bedside: Lessons learned in translating preclinical studies in cancer drug development",
abstract = "The development of targeted agents in oncology has rapidly expanded over the past 2 decades and has led to clinically significant improvements in the treatment of numerous cancers. Unfortunately, not all success at the bench in preclinical experiments has translated to success at the bedside. As preclinical studies shift toward defining proof of mechanism, patient selection, and rational drug combinations, it is critical to understand the lessons learned from prior translational studies to gain an understanding of prior drug development successes and failures. By learning from prior drug development, future translational studies will provide more clinically relevant data, and the underlying hope is that the clinical success rate will improve and the treatment of patients with ineffective targeted therapy will be limited.",
author = "Lieu, {Christopher H.} and Tan, {Aik Choon} and Stephen Leong and Diamond, {Jennifer R.} and Eckhardt, {S Gail}",
year = "2013",
month = "10",
day = "2",
doi = "10.1093/jnci/djt209",
language = "English (US)",
volume = "105",
pages = "1441--1456",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "19",

}

TY - JOUR

T1 - From bench to bedside

T2 - Lessons learned in translating preclinical studies in cancer drug development

AU - Lieu, Christopher H.

AU - Tan, Aik Choon

AU - Leong, Stephen

AU - Diamond, Jennifer R.

AU - Eckhardt, S Gail

PY - 2013/10/2

Y1 - 2013/10/2

N2 - The development of targeted agents in oncology has rapidly expanded over the past 2 decades and has led to clinically significant improvements in the treatment of numerous cancers. Unfortunately, not all success at the bench in preclinical experiments has translated to success at the bedside. As preclinical studies shift toward defining proof of mechanism, patient selection, and rational drug combinations, it is critical to understand the lessons learned from prior translational studies to gain an understanding of prior drug development successes and failures. By learning from prior drug development, future translational studies will provide more clinically relevant data, and the underlying hope is that the clinical success rate will improve and the treatment of patients with ineffective targeted therapy will be limited.

AB - The development of targeted agents in oncology has rapidly expanded over the past 2 decades and has led to clinically significant improvements in the treatment of numerous cancers. Unfortunately, not all success at the bench in preclinical experiments has translated to success at the bedside. As preclinical studies shift toward defining proof of mechanism, patient selection, and rational drug combinations, it is critical to understand the lessons learned from prior translational studies to gain an understanding of prior drug development successes and failures. By learning from prior drug development, future translational studies will provide more clinically relevant data, and the underlying hope is that the clinical success rate will improve and the treatment of patients with ineffective targeted therapy will be limited.

UR - http://www.scopus.com/inward/record.url?scp=84885449125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885449125&partnerID=8YFLogxK

U2 - 10.1093/jnci/djt209

DO - 10.1093/jnci/djt209

M3 - Review article

C2 - 24052618

AN - SCOPUS:84885449125

VL - 105

SP - 1441

EP - 1456

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 19

ER -